• Products
  • Patients
  • Providers
  • About Us
  • Contact
  • Customers
  • Virtual Booth
  • News
  • Media
  • Events
  • Careers
  • Search
  • Toggle side navigation
  • Virtual Booth
  • News
  • Media
  • Events
  • Careers

Are You Seeing The Full Picture?

Since the delivery of our first ultra-widefield device in 2000, Optos has continued to gather clinical evidence about the importance of seeing the peripheral retina especially in patients with diabetes.  optomap is the only ultra-widefield retinal imaging technology that captures up to 200° of the retina in a single image.

  • optomap is clinically validated and supported by over 550 completed and ongoing clinical studies.

  • optomap results are equal to ETDRS in all categories.1 

  • optomap imaging demonstrates that diabetic lesions that occur outside of the ETDRS 7 standard fields predict increased risk of diabetic retinopathy progression over a 4 year period. 2

  • Ultra-widefield retinal evaluation provides information that is necessary to completely assess the risk of DR progression.3

1,2,3 - Data on file

Let's collaborate and bring consistent, evidence-based, high-quality eyecare to integrated healthcare systems.
I would like to receive communications from Optos

You are now leaving the Global site. To change your language, make a selection at the bottom of the page.

Ok Cancel

You are now leaving the Global site. To change your language, make a selection at the bottom of the page.

Ok Cancel
Deutsch Français
English
  • Distributor Portal
  • Find a Doctor
  • Registered in Scotland
  • Blog
  • Unsubscribe
  • Manage Preferences
  • Privacy
  • UK Modern Slavery Act
  • Cookie Policy

© 2021 Optos. Optos, optos and optomap are registered trademarks of Optos plc. UWF is an Optos trademark.